CRISPR Therapeutics AG (NASDAQ:CRSP) Holdings Increased by Axxcess Wealth Management LLC

Axxcess Wealth Management LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 10.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,945 shares of the company’s stock after acquiring an additional 905 shares during the period. Axxcess Wealth Management LLC’s holdings in CRISPR Therapeutics were worth $678,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Riggs Asset Managment Co. Inc. raised its holdings in shares of CRISPR Therapeutics by 66.7% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock worth $34,000 after purchasing an additional 200 shares in the last quarter. Orion Capital Management LLC lifted its position in shares of CRISPR Therapeutics by 44.0% during the 1st quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock valued at $49,000 after acquiring an additional 220 shares during the last quarter. Wealthcare Advisory Partners LLC boosted its stake in shares of CRISPR Therapeutics by 7.7% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 4,200 shares of the company’s stock worth $286,000 after acquiring an additional 300 shares in the last quarter. E Fund Management Co. Ltd. boosted its stake in shares of CRISPR Therapeutics by 3.3% during the 4th quarter. E Fund Management Co. Ltd. now owns 9,460 shares of the company’s stock worth $592,000 after acquiring an additional 303 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its holdings in shares of CRISPR Therapeutics by 55.5% in the 1st quarter. Geneos Wealth Management Inc. now owns 871 shares of the company’s stock worth $59,000 after acquiring an additional 311 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $56.09, for a total value of $188,798.94. Following the transaction, the chief operating officer now owns 6,745 shares of the company’s stock, valued at $378,327.05. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock traded up $0.35 during midday trading on Friday, reaching $57.92. 866,815 shares of the company’s stock traded hands, compared to its average volume of 1,603,022. CRISPR Therapeutics AG has a 52 week low of $37.55 and a 52 week high of $91.10. The company’s 50 day simple moving average is $57.16 and its 200 day simple moving average is $63.57. The company has a market cap of $4.92 billion, a price-to-earnings ratio of -21.28 and a beta of 1.70.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The business had revenue of $0.50 million during the quarter, compared to the consensus estimate of $25.53 million. CRISPR Therapeutics’s quarterly revenue was down 99.5% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.67) EPS. As a group, equities research analysts predict that CRISPR Therapeutics AG will post -5.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $88.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, June 27th. Piper Sandler reissued an “overweight” rating and issued a $105.00 target price on shares of CRISPR Therapeutics in a research report on Monday, June 17th. Barclays reduced their price target on shares of CRISPR Therapeutics from $80.00 to $67.00 and set an “equal weight” rating for the company in a research report on Thursday, May 9th. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, May 9th. Finally, Robert W. Baird boosted their target price on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the company a “neutral” rating in a research note on Thursday, May 9th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $75.71.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.